Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07095205 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine.

Study acronym: VATMDDNicotine
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
In the brain, certain nerve cells communicate using a chemical called acetylcholine. Acetylcholine is thought to be important for several functions including mood, memory and wakefulness. The purpose of this study is to explore the role of these nerve cells in depression. Also, we would like to understand how nicotine, the study drug, works in depression and how it affects these nerve cells. To do this, brain imaging will be used before and after this treatment.
Trial Details
NCT Number NCT07095205
Lead Sponsor Stony Brook University
Collaborators: National Institutes of Health (NIH), National Institute of Mental Health (NIMH)
Conditions
(from sponsor)		 Major Depressive Disorder (MDD)
Related terms Major Depressive Disorder
Enrollment 14 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov